Ventana ALK D5F3 CDx assay (Ventana ALK (D5F3) CDx Assay, Ventana Medical Systems, Tucson, AZ, U.S.A.)has been approved by the FDA as a companion diagnostic and predictive kit for using crizotinib in patients with non-small cell lung cancer [168]. Here, ALK is linked to non-small cell lung carcinoma.